Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Peptide receptor radionuclide therapy for neuroendocrine tumours: standardized and randomized, or personalized?

Literature DB >> 24221244

Peptide receptor radionuclide therapy for neuroendocrine tumours: standardized and randomized, or personalized?

Michael S Hofman¹, Rodney J Hicks.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2013 PMID： 24221244 DOI： 10.1007/s00259-013-2621-6

Source DB: PubMed Journal: Eur J Nucl Med Mol Imaging ISSN： 1619-7070 Impact factor: 9.236

× No keyword cloud information.

19 in total

1. The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy.

Authors: Jean-Mathieu Beauregard; Michael S Hofman; Grace Kong; Rodney J Hicks
Journal: Eur J Nucl Med Mol Imaging Date: 2011-09-20 Impact factor: 9.236

Review 2. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials.

Authors: Gordon C S Smith; Jill P Pell
Journal: BMJ Date: 2003-12-20

3. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Authors: Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski
Journal: N Engl J Med Date: 2011-02-10 Impact factor: 91.245

4. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.

Authors: Jonathan R Strosberg; Robert L Fine; Junsung Choi; Aejaz Nasir; Domenico Coppola; Dung-Tsa Chen; James Helm; Larry Kvols
Journal: Cancer Date: 2010-09-07 Impact factor: 6.860

Review 5. Changing paradigms with molecular imaging of neuroendocrine tumors.

Authors: Michael S Hofman; Rodney J Hicks
Journal: Discov Med Date: 2012-07 Impact factor: 2.970

Review 6. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

Authors: E P Krenning; D J Kwekkeboom; W H Bakker; W A Breeman; P P Kooij; H Y Oei; M van Hagen; P T Postema; M de Jong; J C Reubi
Journal: Eur J Nucl Med Date: 1993-08

Review 7. Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy.

Authors: R J Hicks
Journal: Cancer Imaging Date: 2010-10-04 Impact factor: 3.909

8. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.

Authors: Anja Rinke; Hans-Helge Müller; Carmen Schade-Brittinger; Klaus-Jochen Klose; Peter Barth; Matthias Wied; Christina Mayer; Behnaz Aminossadati; Ulrich-Frank Pape; Michael Bläker; Jan Harder; Christian Arnold; Thomas Gress; Rudolf Arnold
Journal: J Clin Oncol Date: 2009-08-24 Impact factor: 44.544

9. Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide.

Authors: Ebrahim S Delpassand; Amin Samarghandi; Jennifer Sims Mourtada; Sara Zamanian; Gregory D Espenan; Roozbeh Sharif; Shawn Mackenzie; Kambiz Kosari; Omar Barakat; Shagufta Naqvi; John E Seng; Lowell Anthony
Journal: Theranostics Date: 2012-05-11 Impact factor: 11.556

10. Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network.

Authors: Maria P Brizzi; Alfredo Berruti; Anna Ferrero; Enrica Milanesi; Marco Volante; Federico Castiglione; Nadia Birocco; Sebastiano Bombaci; Davide Perroni; Benedetta Ferretti; Oscar Alabiso; Libero Ciuffreda; Oscar Bertetto; Mauro Papotti; Luigi Dogliotti
Journal: BMC Cancer Date: 2009-11-03 Impact factor: 4.430

11 in total

1. The difference between medicine and magic is that magicians know what they are doing.

Authors: Rodney J Hicks
Journal: Eur J Nucl Med Mol Imaging Date: 2015-01 Impact factor: 9.236

Review 2. Peptide Receptor Radiotherapy: Current Approaches and Future Directions.

Authors: Grace Kong; Rodney J Hicks
Journal: Curr Treat Options Oncol Date: 2019-08-29

3. Most medical practices are not parachutes: a citation analysis of practices felt by biomedical authors to be analogous to parachutes.

Authors: Michael J Hayes; Victoria Kaestner; Sham Mailankody; Vinay Prasad
Journal: CMAJ Open Date: 2018-01-15

4. ⁶⁴Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy.

Authors: Rodney J Hicks; Price Jackson; Grace Kong; Robert E Ware; Michael S Hofman; David A Pattison; Timothy A Akhurst; Elizabeth Drummond; Peter Roselt; Jason Callahan; Roger Price; Charmaine M Jeffery; Emily Hong; Wayne Noonan; Alan Herschtal; Lauren J Hicks; Amos Hedt; Matthew Harris; Brett M Paterson; Paul S Donnelly
Journal: J Nucl Med Date: 2018-11-15 Impact factor: 10.057

5. Theranostic implications of molecular imaging phenotype of well-differentiated pulmonary carcinoid based on ⁶⁸Ga-DOTATATE PET/CT and ¹⁸F-FDG PET/CT.

Authors: Lamiaa Zidan; Amir Iravani; Grace Kong; Tim Akhurst; Michael Michael; Rodney J Hicks
Journal: Eur J Nucl Med Mol Imaging Date: 2020-06-22 Impact factor: 9.236

6. High clinical and morphologic response using ⁹⁰Y-DOTA-octreotate sequenced with ¹⁷⁷Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours.

Authors: Grace Kong; Jason Callahan; Michael S Hofman; David A Pattison; Tim Akhurst; Michael Michael; Peter Eu; Rodney J Hicks
Journal: Eur J Nucl Med Mol Imaging Date: 2016-09-27 Impact factor: 9.236

7. Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis.

Authors: Sue Ping Thang; Mei Sim Lung; Grace Kong; Michael S Hofman; Jason Callahan; Michael Michael; Rodney J Hicks
Journal: Eur J Nucl Med Mol Imaging Date: 2017-09-12 Impact factor: 9.236

8. Long-Term Follow-up and Outcomes of Retreatment in an Expanded 50-Patient Single-Center Phase II Prospective Trial of ¹⁷⁷Lu-PSMA-617 Theranostics in Metastatic Castration-Resistant Prostate Cancer.

Authors: John Violet; Shahneen Sandhu; Amir Iravani; Justin Ferdinandus; Sue-Ping Thang; Grace Kong; Aravind Ravi Kumar; Tim Akhurst; David A Pattison; Alexis Beaulieu; Jennifer Mooi; Ben Tran; Christina Guo; Victor Kalff; Declan G Murphy; Price Jackson; Peter Eu; Mark Scalzo; Scott Williams; Rodney J Hicks; Michael S Hofman
Journal: J Nucl Med Date: 2019-11-15 Impact factor: 11.082

9. Lutetium-177 DOTATATE Production with an Automated Radiopharmaceutical Synthesis System.

Authors: Alireza Aslani; Graeme M Snowdon; Dale L Bailey; Geoffrey P Schembri; Elizabeth A Bailey; Nick Pavlakis; Paul J Roach
Journal: Asia Ocean J Nucl Med Biol Date: 2015

10. Tumor Sink Effect in ⁶⁸Ga-PSMA-11 PET: Myth or Reality?

Authors: Andrei Gafita; Hui Wang; Andrew Robertson; Wesley R Armstrong; Raphael Zaum; Manuel Weber; Farid Yagubbayli; Clemens Kratochwil; Tristan R Grogan; Kathleen Nguyen; Fernando Navarro; Rouzbeh Esfandiari; Isabel Rauscher; Bjoern Menze; David Elashoff; Ebrahim S Delpassand; Ken Herrmann; Johannes Czernin; Michael S Hofman; Jeremie Calais; Wolfgang P Fendler; Matthias Eiber
Journal: J Nucl Med Date: 2021-05-28 Impact factor: 11.082